SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

NEXGEL, Inc. NXGL NASDAQ

NASDAQ Capital Marke • Healthcare • Medical - Instruments & Supplies • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

NEXGEL, Inc. (NXGL) is a Medical - Instruments & Supplies company in the Healthcare sector, currently trading at $0.59. It has a SharesGrow Score of 44/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Valuation: NXGL trades at a trailing Price-to-Earnings (P/E) of -1.6 (S&P 500 average ~25).

Financials: revenue is $11M, +81.2%/yr average growth. Net income is $3M (loss), growing at +17.8%/yr. Net profit margin is -26.3% (negative). Gross margin is 39.5% (+27 pp trend).

Balance sheet: total debt is $3M against $4M equity (Debt-to-Equity (D/E) ratio 0.67, moderate). Current ratio is 1.47 (adequate). Debt-to-assets is 28.6%. Total assets: $10M.

Analyst outlook: 1 / 1 analysts rate NXGL as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 90/100 (Pass), Past 0/100 (Fail), Health 33/100 (Fail), Moat 36/100 (Fail), Future 100/100 (Pass), Income 10/100 (Fail).

NXGL SharesGrow Score Overview

54/100

SharesGrow Score

Mixed signals — some strengths

View full scorecard →

VALUE 0/100

Valuation — P/E, PEG, Forward PEG

GROWTH 90/100

Financials — average growth

PAST 0/100

strong — trend

HEALTH 33/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 36/100

Gross margin is + market cap

FUTURE 100/100

Analyst outlook — as buy

INCOME 10/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — NXGL

No analyst coverage available for this stock.

NXGL: +81.2%/yr revenue is, +17.8%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

No analyst coverage available for this stock.

Balance sheet NXGL: Debt-to-Equity (D/E) ratio 0.67 (moderate), Current ratio is 1.47 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

NXGL: Gross margin is 39.5% (+27 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 36/100. ≥ 70 = Pass.

View details →

Analyst outlook: 1 / 1 analysts rate NXGL as buy (100%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

NXGL: Net profit margin is -26.3%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range0.577-3.019

Volume111.09K

Avg Volume (30D)272.52K

Market Cap$6.34M

Beta (1Y)0.62

Share Statistics

EPS (TTM)-0.38

Shares Outstanding$7.85M

IPO Date2021-12-22

Employees19

CEOAdam R. Levy

Financial Highlights & Ratios

Revenue (TTM)$11.42M

Gross Profit$4.51M

EBITDA$-3.35M

Net Income$-3M

Operating Income$-3.35M

Total Cash$317K

Total Debt$2.99M

Net Debt$2.67M

Total Assets$10.46M

Price / Earnings (P/E)-1.6

Price / Sales (P/S)0.55

Analyst Forecast

Rating ConsensusBuy

Analysts Covering1

Buy 100% Hold 0% Sell 0%

Company Info

CountryUS

ExchangeNASDAQ Capital Marke

CurrencyUSD

ISINUS65344E1073

Price Chart

NXGL

NEXGEL, Inc. ↗ · NASDAQ Capital Marke

Healthcare • Medical - Instruments & Supplies

0.58 52WK RANGE 3.02

People Also View

Daxor Corporation

Sharps Technology, Inc.

Milestone Scientific Inc.

Jin Medical International Ltd.

Innovative Eyewear, Inc.

Predictive Oncology Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message